Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06313398
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2024-03-14
Brief Title:
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
Sponsor:
National Heart Lung and Blood Institute NHLBI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
Status:
RECRUITING
Status Verified Date:
2024-07-26
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Background
Sickle cell disease SCD is an inherited disorder of the blood SCD causes red blood cells RBCs to die early This can lead to a shortage of healthy cells SCD and other blood disorders can be managed with drugs or cured with a bone marrow transplant Researchers want to know how long RBCs survive in people with SCD and other blood disorders before and after treatment compared to those who had a bone marrow transplant
Objective
To learn how long RBCs survive in the body in people with SCD and other blood disorders compared to those whose disease was cured with a bone marrow transplant
Eligibility
People aged 18 years or older with SCD or another inherited blood disorder People whose SCD or blood disorder was cured with a bone marrow transplant are also needed
Design
Participants will be screened They will have a physical exam with blood and urine tests
Participants will have about 7 tablespoons of blood drawn In the lab this blood will be mixed with a vitamin called biotin Biotin sticks to the outside of RBCs This process is called biotin labeling of RBCs The next day the participant s own biotin-labeled RBCs will be returned to their bloodstream
Participants will return regularly to have smaller blood samples about 2 teaspoons drawn These samples will be tested to detect the percentage of cells that have biotin labels These visits may be every 2 weeks 4 weeks or some other interval Participants will continue this schedule for up to 20 weeks or until biotin can no longer be detected
Sickle cell disease SCD is an inherited disorder of the blood SCD causes red blood cells RBCs to die early This can lead to a shortage of healthy cells SCD and other blood disorders can be managed with drugs or cured with a bone marrow transplant Researchers want to know how long RBCs survive in people with SCD and other blood disorders before and after treatment compared to those who had a bone marrow transplant
Objective
To learn how long RBCs survive in the body in people with SCD and other blood disorders compared to those whose disease was cured with a bone marrow transplant
Eligibility
People aged 18 years or older with SCD or another inherited blood disorder People whose SCD or blood disorder was cured with a bone marrow transplant are also needed
Design
Participants will be screened They will have a physical exam with blood and urine tests
Participants will have about 7 tablespoons of blood drawn In the lab this blood will be mixed with a vitamin called biotin Biotin sticks to the outside of RBCs This process is called biotin labeling of RBCs The next day the participant s own biotin-labeled RBCs will be returned to their bloodstream
Participants will return regularly to have smaller blood samples about 2 teaspoons drawn These samples will be tested to detect the percentage of cells that have biotin labels These visits may be every 2 weeks 4 weeks or some other interval Participants will continue this schedule for up to 20 weeks or until biotin can no longer be detected
Detailed Description:
Study Description
This study will use biotin-labeling of red blood cells RBCs to determine the mean potential lifespan MPL of RBCs in patients with sickle cell disease SCD and other hemoglobinopathies eg thalassemia including in those receiving disease modifying therapies or who have undergone curative hematopoietic stem cell transplantation HSCT allogeneic or autologous Previous studies have corroborated the MPL of healthy donor RBCs to be approximately 115 days while RBCs from patients with SCD have a more variable but consistently shorter MPL of approximately 32 days We recently validated these findings and demonstrated the feasibility safety and efficacy of determining MPL of biotin-labeled RBCs in patients with SCD before and after transplant persons with sickle cell trait and healthy donors Allogeneic HSCT is a curative treatment for severe SCD with stable mixed donor-recipient chimerism after HSCT sufficient to reverse the sickle cell phenotype by virtue of improved donor red cell survival compared to the ineffective erythropoiesis of SCD HSCT both allogeneic and autologous are also curative for certain hemoglobinopathies such as transfusion dependent beta thalassemia TDT with donor cells able to overcome the ineffective erythropoiesis in TDT as well We predict that the hematologic variables associated with red cell survival among patients with SCD and other hemoglobinopathies vary between individuals and are affected by disease modifying therapy including curative therapies The data generated will refine our understanding of the degree of correction necessary to reverse the clinical phenotype of SCD and other hemoglobinopathies including that needed for autologous gene therapy to be curative
Objectives
Primary Objective
To determine and compare red blood cell survival by virtue of the mean number of days of detectable biotin-labeled RBCs in participants with SCD andor other hemoglobinopathies before and after initiation of disease modifying therapy including those who have undergone HSCT
Secondary Objective
To validate the association of red cell survival with known markers of increased survival specifically absolute reticulocyte count hemoglobin F or hemoglobin A percentage and alpha globin mutation status SCD participants only
Exploratory Objective
To create and pilot a mathematical model incorporating RBC survival and reticulocyte count to determine the necessary amount of normal hemoglobin or hemoglobin F needed to reverse sickle cell complications Information from participants with inherited high HbF will be used
Endpoints
Primary Endpoint
Red blood cell survival via measurement of detectable biotin-labeled RBC with time
Secondary Endpoint
Relationship of RBC survival to hematologic parameters
Exploratory Endpoint
Amount of normal hemoglobin or hemoglobin F needed to reverse the sickle cell complications
This study will use biotin-labeling of red blood cells RBCs to determine the mean potential lifespan MPL of RBCs in patients with sickle cell disease SCD and other hemoglobinopathies eg thalassemia including in those receiving disease modifying therapies or who have undergone curative hematopoietic stem cell transplantation HSCT allogeneic or autologous Previous studies have corroborated the MPL of healthy donor RBCs to be approximately 115 days while RBCs from patients with SCD have a more variable but consistently shorter MPL of approximately 32 days We recently validated these findings and demonstrated the feasibility safety and efficacy of determining MPL of biotin-labeled RBCs in patients with SCD before and after transplant persons with sickle cell trait and healthy donors Allogeneic HSCT is a curative treatment for severe SCD with stable mixed donor-recipient chimerism after HSCT sufficient to reverse the sickle cell phenotype by virtue of improved donor red cell survival compared to the ineffective erythropoiesis of SCD HSCT both allogeneic and autologous are also curative for certain hemoglobinopathies such as transfusion dependent beta thalassemia TDT with donor cells able to overcome the ineffective erythropoiesis in TDT as well We predict that the hematologic variables associated with red cell survival among patients with SCD and other hemoglobinopathies vary between individuals and are affected by disease modifying therapy including curative therapies The data generated will refine our understanding of the degree of correction necessary to reverse the clinical phenotype of SCD and other hemoglobinopathies including that needed for autologous gene therapy to be curative
Objectives
Primary Objective
To determine and compare red blood cell survival by virtue of the mean number of days of detectable biotin-labeled RBCs in participants with SCD andor other hemoglobinopathies before and after initiation of disease modifying therapy including those who have undergone HSCT
Secondary Objective
To validate the association of red cell survival with known markers of increased survival specifically absolute reticulocyte count hemoglobin F or hemoglobin A percentage and alpha globin mutation status SCD participants only
Exploratory Objective
To create and pilot a mathematical model incorporating RBC survival and reticulocyte count to determine the necessary amount of normal hemoglobin or hemoglobin F needed to reverse sickle cell complications Information from participants with inherited high HbF will be used
Endpoints
Primary Endpoint
Red blood cell survival via measurement of detectable biotin-labeled RBC with time
Secondary Endpoint
Relationship of RBC survival to hematologic parameters
Exploratory Endpoint
Amount of normal hemoglobin or hemoglobin F needed to reverse the sickle cell complications
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 001883-H | None | None | None |